KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Account Payables (2018 - 2025)

Castle Biosciences' Change in Account Payables history spans 7 years, with the latest figure at -$17000.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 97.02% year-over-year to -$17000.0; the TTM value through Dec 2025 reached $3.1 million, up 170.4%, while the annual FY2025 figure was $3.1 million, 170.4% up from the prior year.
  • Change in Account Payables for Q4 2025 was -$17000.0 at Castle Biosciences, down from $1.4 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $3.9 million in Q1 2023 and bottomed at -$2.2 million in Q3 2024.
  • The 5-year median for Change in Account Payables is -$28500.0 (2021), against an average of $240650.0.
  • The largest annual shift saw Change in Account Payables plummeted 1935.71% in 2021 before it skyrocketed 1983.42% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at -$855000.0 in 2021, then tumbled by 83.98% to -$1.6 million in 2022, then soared by 291.61% to $3.0 million in 2023, then tumbled by 118.91% to -$570000.0 in 2024, then surged by 97.02% to -$17000.0 in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Change in Account Payables are -$17000.0 (Q4 2025), $1.4 million (Q3 2025), and $1.1 million (Q2 2025).